[Correspondence] Questions in the design of ANSWER – Authors’ reply
We thank Ian A Rowe and Richard Parker for their interest in our study and their comments.1 They point out that refractory ascites was an endpoint in the trial and that participants were censored with that event. Indeed, refractory ascites was a secondary endpoint, along with the occurrence of other complications of cirrhosis. However, patients developing refractory ascites were not censored and continued to be followed up. In fact, 12 cases of liver transplantation or transjugular intrahepatic porto-systemic shunt (TIPS) insertion and 25 deaths (15 in the standard-treatment group and ten in the albumin group) were observed after onset of refractory ascites.